ArticleCureus2025
Overlapping Pathways: Autism Spectrum Disorder in Fragile X Carrier States and the Need for Greater Awareness.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fragile X syndrome (FXS), caused by a full mutation (>200 CGG repeats) in the gene Fragile X messenger ribonucleoprotein 1 (FMR1), is the most common single-gene cause of autism spectrum disorder (ASD). Far less is known about the clinical significance of smaller FMR1 expansions. In this case series, we describe four male patients with ASD who carried the FMR1 intermediate (gray-zone) alleles (45-50 CGG; counts: 45, 49, 49, 50). All had early speech/language delay with ASD-consistent features (social-communication deficits, sensory sensitivities, and repetitive behaviors). Common comorbidities included attention-deficit/hyperactivity disorder (ADHD) features and sleep disturbance responsive to standard interventions. None of them met premutation (55-200 CGG) or full-mutation criteria. These observations align with emerging evidence that gray-zone alleles can be associated with neurodevelopmental phenotypes, including ASD traits, in a subset of carriers. Clinically, the series reinforces guidance to include FMR1 analysis in genetic evaluations for unexplained developmental delay/ASD and to provide counseling when intermediate results are identified. Awareness of a potential overlap between the FMR1 gray-zone states and ASD may aid comprehensive evaluation and family counseling. Larger, controlled studies, especially those incorporating AGG interruption analysis, are needed to quantify risk and clarify mechanisms underlying phenotypic variability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.